Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganfeborole SCHEMBL31152062 | 1.00 | LARS1 (0.75) | LARS1 | |
| Ganfeborole SCHEMBL18023952 | 1.00 | LARS1 (0.75) | LARS1 | |
| Ganfeborole SCHEMBL29880374 | 0.99 | LARS1 (0.76) | LARS1 | |
| SCHEMBL5019532 | 0.94 | LARS1 (0.73) | LARS1 | |
| Hydrochloric Acid SCHEMBL462689 | 0.93 | LARS1 (0.74) | LARS1 | |
| Hydrochloric Acid SCHEMBL2679967 | 0.91 | LARS1 (0.70) | LARS1 | |
| SCHEMBL460683 | 0.90 | LARS1 (0.75) | LARS1 | |
| SCHEMBL453971 | 0.89 | LARS1 (0.73) | LARS1 | |
| Hydrochloric Acid SCHEMBL2679363 | 0.88 | LARS1 (0.74) | LARS1 | |
| SCHEMBL5019556 | 0.88 | LARS1 (0.80) | LARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4121058-B1 | OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2026-02-18 | — | — | EP | claimed |
| US-12435077-B2 | Oxazolidinone compound and methods of use thereof as an antibacterial agent | MERCK SHARP & DOHME LLC (US) | 2025-10-07 | — | — | US | claimed |
| US-20250129084-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-24 | — | — | US | claimed |
| WO-2025051102-A1 | DEUTERATED TETRACYCLIC DERIVATIVE AND USE THEREOF | 浙江我武翼方药业有限公司 | 2025-03-13 | — | — | WO | claimed |
| CN-119591611-A | Deuterated tetracyclic derivative and application thereof | 浙江我武翼方药业有限公司 | 2025-03-11 | — | — | CN | claimed |
| EP-4486454-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-01-08 | — | — | EP | claimed |
| WO-2024256554-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-19 | — | — | WO | claimed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | claimed |
| US-20240208958-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | claimed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | claimed |
| WO-2023156648-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-24 | — | — | WO | claimed |
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | claimed |
| EP-4121058-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | Merck Sharp & Dohme LLC (US) | 2023-01-25 | — | — | EP | claimed |
| CN-110997651-B | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-110997680-B | Novel compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-10-21 | — | — | CN | claimed |
| US-11253499-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| US-11254689-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| EP-4747301-A2 | HYDROGELS EXHIBITING BORONATE ESTER-MEDIATED DRUG RELEASE | William Marsh Rice University (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2016128949-A1 | BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435077-B2 | Oxazolidinone compound and methods of use thereof as an antibacterial agent | OXA1L, IL17A, TBCD | LARS1 4350/4885 |
| US-20250129084-A1 | Compounds | CFTR, TBCA, TBCD | LARS1 3349/4885 |
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | LARS1 3435/4885 |
| US-11253499-B2 | Compounds | SDHA, SDHB, FDPS | LARS1 3086/4885 |
| US-20240208958-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | OXA1L, IL17A, TBCD | LARS1 4350/4885 |
| US-11254689-B2 | Compounds | SDHA, SDHB, FDPS | LARS1 3086/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | LARS1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.